Effect of transtympanic injection of melatonin on cisplatin-induced ototoxicity

Journal of International Advanced Otology

Volumn 11, Issue 3, 2015, Pages 202-206

  Demir, Mehmet Gökhan ^a   Altıntoprak, Niyazi ^b   Aydın, Sedat ^c   Kösemihal, Ebru ^d   Başak, Kayhan ^c  

^a Prof Dr Celal Ertu Etimesgut State Hospital   (Turkey)

^b Otolaryngology Clinic   (Turkey)

^c DR LUTFI KIRDAR KARTAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d MARMARA UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Cochlea; Melatonin; Ototoxicity; Transtympanic

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CISPLATIN; MELATONIN;

ANIMAL; AUDITORY THRESHOLD; CHEMICALLY INDUCED; COCHLEA; DRUG EFFECTS; EAR DISEASES; EARDRUM; EPITHELIUM; EVOKED BRAIN STEM AUDITORY RESPONSE; INJECTION; MALE; PATHOLOGY; PATHOPHYSIOLOGY; SPONTANEOUS OTOACOUSTIC EMISSION; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; AUDITORY THRESHOLD; CISPLATIN; COCHLEA; EAR DISEASES; EPITHELIUM; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; INJECTIONS; MALE; MELATONIN; OTOACOUSTIC EMISSIONS, SPONTANEOUS; RATS, WISTAR; TYMPANIC MEMBRANE;

EID: 84975702123     PISSN: 13087649     EISSN: None     Source Type: Journal    
DOI: 10.5152/iao.2015.1094     Document Type: Article

References (24)

1. Gabaizadeh R, Staecker H, Liu W, Kopke R, Malgrange B, Lefebvre PP, et al. Protection of both auditory hair cells and auditory neuronsfrom cisplatin induced damage. Acta Otolaryngol (Stockh) 1997; 117: 232-8. [CrossRef]
2. Rybak LP, Ravi R, Somani SM. Mechanism of protection by diethyldihydrothiocarbamate against cisplatin ototoxicity: Antioxidant system. Fund Appl Toxicol 1995; 26: 293-300. [CrossRef]
3. Rybak LP, Husain K, Evenson L, Morris C, Whitworth C, Somani SM. Protection by 4-methylthiobenzoic acid against cisplatin-induced ototoxicity: Antioxidant system. Pharmacol Toxicol 1997; 81: 173-9. [CrossRef]
4. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: Antioxidant system. Pharmacol Toxicol 1995; 76: 386-94. [CrossRef]
5. Ford MS, Nie Z, Whitworth C, Rybak LP, Ramkumar V. Up-regulation of adenosine receptors in the cochlea by cisplatin. Hearing Res 1997; 111: 143-52. [CrossRef]
6. Campbell KC, Rybak LP, Meech RP, Hugher L. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hearing Res 1996; 102: 90-8. [CrossRef]
7. Clerici WJ. Effects of superoxide dismutase and U74389G on acute trimethyltin-induced cochlear dysfunction. Toxicol Appl Pharmacol 1996; 136: 236-42. [CrossRef]
8. Clerici WJ, Yang L. Direct effects of intraperilymphatic reactive oxygen species generation on cochlear function. Hearing Res 1996; 101: 14-22. [CrossRef]
9. Reppert SM, Weaver DR, Rıvkees SA, Stopa EG. Putative melatonin receptors in a human biological clock. Science 1989; 242: 78-81. [CrossRef]
10. Lopez-Gonzalez MA, Calvo JR, Rubio A, Goberna R, Guerrero JM. Characterization of melatonin binding sites in the Harderian gland and median eminence of the rat. Life Sci 1991; 48: 1165-71. [CrossRef]
11. Dubocovich ML. Characterization of a retinal melatonin receptor. J Pharmacol Exp Ther 1985; 234: 395-401.
12. Biesalski HK, Welker HA, Thalmann R, Vollrath L. Melatonin and other serotonin derivatives in the guinea pig membranous cochlea. Neurosci Lett 1998; 91: 41-6. [CrossRef]
13. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: A potent endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
14. Babu E, Gopalkrishnan VK, Sriganth INP. Gopalkrishnan R, Sakthisekaran D. Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol Cell Biochem 1995; 144: 7-11. [CrossRef]
15. Tan DX, Manchester LC, Reiter RJ, Plummer BF, Hardies LJ, Weintraub ST, et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem Biophys Res Commun 1998; 253: 614-20. [CrossRef]
16. Tan DX, Manchester LC, Burkhardt, Sainz RM, Mayo JC, Kohen R, et al. N1-acetyl-N2- formyl-5-methoxykynuramine, a biogenic amine andmelatonin metabolite, functions as a potent antioxidant. FASEB J 2001; 15: 2294-6.
17. Ressmeyer AR, Mayo JC, Zelosko V, Sainz RM, Tan DX, Poeggeler B, et al. Antioxidant properties of the melatonin metabolite, N1-acetyl-5-methoxykynuramine (AMK): scavenging of free radicals and prevention of protein destruction. Redox Rep 2003; 8: 205-13. [CrossRef]
18. Urata Y, Homna S, Goto S, Todoroki S, Lida T, Cho S, et al. Melatonin induces gammaglutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Rad Biol Med 1999; 27: 838-47. [CrossRef]
19. Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol 2000; 5: 3-22. [CrossRef]
20. Lopez-Gonzalez MA, Guerrero JM, Roias F, Delgado F. Ototoxicity caused by cisplatin is ameliorated by melatonin and other antioxidants. J Pineal Res. 2000; 28: 73-80. [CrossRef]
21. Erdem T, Ozturan O, Iraz M, Mimam MC, Olmez E. Dose-dependent dual effect of melatonin on ototoxicity induced by amikacin in adult rats. Eur Arch Otorhinolaryngol 2005; 262: 314-21. [CrossRef]
22. Juhn SK, Hamaguchi Y, Goycoolea M. Review of round window mebrane permeability. Acta otolaryngol (Stockh) 1988; 457: 43-8. [CrossRef]
23. Geary GG, Krause DN, Duckles SP. Melatonin directly constricts rat cerebral arteries through modulation of potassium channels. Am J Physiol 1997; 273: H1530-6.
24. Ye LF, Tao ZZ, Hua QQ, Xiao BK, Zhou XH, Li J, et al. Protective effect of melatonin against gentamicin ototoxicity. J Laryngol Otol 2009; 123: 598-602. [CrossRef]